Prognostic Value of Bcl-xL in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.

J Oral Pathol MedJun 13, 2026 (epub)
Clinical ResearchOncology (Medical)Open access

L Leinonen, R Tiikkaja, M Juola et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the prognostic value of Bcl-xL in head and neck squamous cell carcinoma, analyzing 20 studies. While high Bcl-xL levels were rarely linked to overall survival, they correlated with increased lymph node metastasis in 40% of studies. Notably, a specific study on oral tongue cancer found a significant association between high Bcl-xL levels and decreased survival.

Key findings

  • High Bcl-xL levels correlated with increased risk of lymph node metastasis in 40% of studies.
  • A study on oral tongue cancer showed a significant correlation between high Bcl-xL levels and decreased survival.
  • Overall evidence does not support Bcl-xL as a general prognostic marker in head and neck squamous cell carcinoma.

Why it matters

Understanding the prognostic factors in head and neck squamous cell carcinoma is crucial for patient management. While Bcl-xL may not serve as a general marker, its potential relevance in specific subtypes like oral tongue cancer warrants further investigation.

Source

PubMed · PMID 42287032Free full text on PubMed Central

Published in J Oral Pathol Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.